Edwards Lifesciences is planning some important TAVR reveals during the PCR London Valves 2017 course that is underway.
The Irvine, Calif.–based cardio devices company said yesterday that it plans to introduce the new Sapien 3 Ultra valve during the event, which runs until tomorrow.
Edwards officials expect the Sapien 3 Ultra to receive CE Mark by the end of the year, with plans for a U.S. introduction in late 2018. For the Ultra, they’ve added a taller skirt to the Sapien 3 design to improve TAVR outcomes, according to the company.
Edwards has incorporated the taller skirt initially with sizes 20, 23 and 26 mm. Along with the taller skirt, there’s the Sapien 3 Ultra delivery system, which introduces an “on balloon” design that does away with the need for valve alignment during the procedure. The delivery system is compatible with the new 14F Axela expandable sheath.
Other announcements Edwards plans to make during PCR London Valves 2017 include:
Edwards during today’s Late-Breaking TAVI Trials session will discuss new results related to the self-expanding Edwards Centera valve. Previously, 30-day outcomes results for Centera demonstrated a very high survival rate, a low disabling stroke rate and a low percent permanent pacemaker rate.
A sponsored session yesterday was expected to provide a review of the latest clinical trials involving Edwards’ aortic, mitral, tricuspid and pulmonary valve therapies.
A sponsored session tomorrow will focus on the present experience and clinical results related to the Edwards Cardioband system, as well as a discussion of Edwards’ innovations for transcatheter valve therapies.
“As PCR London Valves celebrates 15 years of transcatheter aortic valve replacement, Edwards is proud to have led the development and evolution of TAVR as a preferred therapy for patients in need around the world,” Larry L. Wood, Edwards’ corporate VP of transcatheter heart valves, said in a news release.